OVERVIEW

CJC-1295 no DAC (Mod GRF 1-29) is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) designed to stimulate the body’s natural release of growth hormone (GH) via the pituitary gland. The “no DAC” version — sometimes referred to as Mod GRF 1-29 — has a shorter half-life compared with formulations that include a drug affinity complex (DAC). This shorter duration of action encourages pulsatile GH release, which more closely mirrors the body’s normal physiological secretion patterns. In research settings, Mod GRF 1-29 has been explored for its potential effects on metabolic processes, body composition, recovery, and cellular physiology, primarily by increasing endogenous GH secretion rather than supplying exogenous hormone. Because it primarily stimulates GH secretion through the GHRH receptor, it may lead to downstream effects on insulin-like growth factor-1 (IGF-1) production and related pathways in experimental models.

Despite scientific interest, CJC-1295 no DAC (Mod GRF 1-29) is not approved by the U.S. Food and Drug Administration for therapeutic use in humans, and its safety, efficacy, and optimal dosing have not been established in large, controlled clinical trials. Most of the evidence supporting its biological activity comes from laboratory research, animal studies, or small pilot investigations rather than robust human data. Products marketed with this peptide are often designated for research use only, meaning they are not manufactured to pharmaceutical quality standards, and purity and potency can vary widely. Self-administration outside regulated research environments carries significant safety and ethical considerations. Individuals interested in hormonal health or metabolic therapies should consult qualified healthcare professionals and rely on evidence-based clinical interventions rather than unapproved peptides.